Acorda Therapeutics Inc. (NASDAQ:ACOR) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acorda Therapeutics Inc. 471.43M 1.33 33.68M 0.71 20.63 Citius Pharmaceuticals Inc. N/A 0.00 13.17M -1.06 0.00 In table 1 we can see Acorda Therapeutics Inc. and Citius Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the return on equity, net margins and return on assets of Acorda Therapeutics Inc. and Citius Pharmaceuticals Inc.
Volatility and Risk
Acorda Therapeutics Inc. is 47.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.47. In other hand, Citius Pharmaceuticals Inc. has beta of 1.19 which is 19.00% more volatile than Standard and Poor’s 500.
The Current Ratio and a Quick Ratio of Acorda Therapeutics Inc. are 3.8 and 3.6. Competitively, Citius Pharmaceuticals Inc. has 1.8 and 1.8 for Current and Quick Ratio. Acorda Therapeutics Inc.’s better ability to pay short and long-term obligations than Citius Pharmaceuticals Inc.
The next table highlights the delivered recommendations and ratings for Acorda Therapeutics Inc. and Citius Pharmaceuticals Inc.
Acorda Therapeutics Inc.’s upside potential is 56.95% at a $20.67 consensus price target.
Institutional & Insider Ownership
The shares of both Acorda Therapeutics Inc. and Citius Pharmaceuticals Inc. are owned by institutional investors at 0% and 5% respectively. About 1.4% of Acorda Therapeutics Inc.’s share are held by insiders. Comparatively, Citius Pharmaceuticals Inc. has 44.4% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Acorda Therapeutics Inc. 9.02% -12.03% -29.7% -48.85% -39.92% -6.1% Citius Pharmaceuticals Inc. 6.03% 28.13% 3.36% -16.33% -64.76% 18.27% For the past year Acorda Therapeutics Inc. has -6.1% weaker performance while Citius Pharmaceuticals Inc. has 18.27% stronger performance.
Acorda Therapeutics Inc. beats on 10 of the 11 factors Citius Pharmaceuticals Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke’s Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King’s College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Click here to view original web page at Reviewing Acorda Therapeutics Inc. (ACOR)’s and Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s results